Shulamit Ron-Bigger
Director de Operaciones en Aktis Oncology, Inc. .
Cargos activos de Shulamit Ron-Bigger
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
Aktis Oncology, Inc.
Aktis Oncology, Inc. Medical/Nursing ServicesHealth Services Aktis Oncology, Inc. is a biotechnology company located in Boston, MA. The company specializes in the discovery and development of a new class of targeted alpha radiopharmaceuticals to treat a broad range of solid tumor cancers. The company's molecules are designed for high tumor penetration and long residence time, which maximizes tumor elimination while minimizing side effects of treatment. The approach enables clinicians to visualize and verify target engagement prior to exposure to therapeutic radioisotopes. Founded and incubated by MPM Capital, Aktis Oncology has developed proprietary platforms to generate tumor targeting agents with ideal properties for alpha radiotherapy. Matt M. Roden has been the CEO of the company since 2020. | Director de Operaciones | 19/09/2022 | - |
Historial de carrera de Shulamit Ron-Bigger
Formación de Shulamit Ron-Bigger.
The Hebrew University of Jerusalem | Doctorate Degree |
Estadísticas
Internacional
Estados Unidos | 2 |
Israel | 2 |
Operativa
Chief Operating Officer | 1 |
Doctorate Degree | 1 |
Sectorial
Health Services | 2 |
Consumer Services | 2 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
Empresas privadas | 1 |
---|---|
Aktis Oncology, Inc.
Aktis Oncology, Inc. Medical/Nursing ServicesHealth Services Aktis Oncology, Inc. is a biotechnology company located in Boston, MA. The company specializes in the discovery and development of a new class of targeted alpha radiopharmaceuticals to treat a broad range of solid tumor cancers. The company's molecules are designed for high tumor penetration and long residence time, which maximizes tumor elimination while minimizing side effects of treatment. The approach enables clinicians to visualize and verify target engagement prior to exposure to therapeutic radioisotopes. Founded and incubated by MPM Capital, Aktis Oncology has developed proprietary platforms to generate tumor targeting agents with ideal properties for alpha radiotherapy. Matt M. Roden has been the CEO of the company since 2020. | Health Services |
- Bolsa de valores
- Insiders
- Shulamit Ron-Bigger
- Experiencia